welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
The Traveling J-Pouch: More Tips for Going Abroad with a J-Pouchhttps://www.youtube.com/watch?v=Vk5AmBLF...
-
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
-
Education and Management of Patients with Familial Adenomatous Polyposis. Are We Making Progress? A Case ReportAbstract: A 25-year-old male patient was...
-
Clinical and Genomic Influence of Sulindac on Rectal Mucosa in Familial Adenomatous PolyposisPURPOSE : A study was performed to evalu...
-
Severe Duodenal Involvement in Familial Adenomatous Polyposis Treated by Pylorus-Preserving PancreaticoduodenectomyPURPOSE : Pancreaticoduodenectomy is an ...
-
Gardner Syndrome: Skin Manifestations, Differential Diagnosis and ManagementGardner syndrome is a variant of familia...
-
Laparoscopic-Assisted Proctocolectomy with Prolapsing Technique for Familial Adenomatous PolyposisPURPOSE : The role of laparoscopic total...